Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ceralasertib + Saruparib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ceralasertib | AZD6738|AZD-6738 | ATR Inhibitor 16 | Ceralasertib (AZD6738) is an inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents, potentially resulting in tumor regression (PMID: 26517239, PMID: 31836456). | |
| Saruparib | AZD 5305|AZD-5305|AZD5305 | PARP-1 Inhibitor 13 | Saruparib (AZD5305) inhibits PARP1, potentially leading to tumor growth inhibition (PMID: 35929986). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51C I341M | Advanced Solid Tumor | sensitive | Ceralasertib + Saruparib | Preclinical - Cell culture | Actionable | In a preclinical study, Ceralasertib (AZD6738) and Saruparib (AZD5305) synergistically inhibited colony formation in cell lines expressing RAD51C I341M in culture (PMID: 42625895). | 42625895 |
| RAD51C L230F | Advanced Solid Tumor | sensitive | Ceralasertib + Saruparib | Preclinical - Cell culture | Actionable | In a preclinical study, Ceralasertib (AZD6738) and Saruparib (AZD5305) synergistically inhibited colony formation in cell lines expressing RAD51C L230F in culture (PMID: 42625895). | 42625895 |
| RAD51C D141H | Advanced Solid Tumor | sensitive | Ceralasertib + Saruparib | Preclinical - Cell culture | Actionable | In a preclinical study, Ceralasertib (AZD6738) and Saruparib (AZD5305) synergistically inhibited colony formation in cell lines expressing RAD51C D141H in culture (PMID: 42625895). | 42625895 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|